Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi
  IRCT20180725040596N2		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
50/50 inconclusive
    Nojomi
          IRCT20180725040596N2    		 RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
    		50/50 inconclusive

      COVID 19 all comers meta-analysis

      Chang Chen et al.
              ChiCTR2000030254      		 RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
      		120/120 inconclusive
      • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

      COVID-19 mild to moderate meta-analysis

      Solaymani-Dodaran
              IRCT20200318046812N1      		 RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
      		193/187 inconclusive
        ELACOI (Lopinavir/ritonavir)
                  NCT04252885        		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
        		35/34 inconclusive
        • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
        • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
        GS-US-540-5773 (Goldman)
                  NCT04292899        		 RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
        		200/197 suggested
        • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
        Hung et al.
                  NCT04276688        		 RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
        		86/41 conclusif
        • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
        Ren
                  ChiCTR2000029853        		 RCTazvudineantiviral and associated therapyCOVID-19 mild to moderatesome concern
        		10/10 suggested
        • suggested 27.5-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

        COVID-19 severe or critically meta-analysis

        Galan
                  RBR-8h7q82        		 RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
        		53/115 suggested
        • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
        Galan
                  RBR-8h7q82        		 RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
        		53/115 suggested
        • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
        7 studies excluded by filtering options (3 RCT / 4 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons